AUTHORS
Dimitrios Kotsos, MD, MSc, Robin Visser2, Dana Chitu, PhD, MSc3, Saskia Klein, MD, PhD4, Maarten Corsten, MD, PhD5, Rinske S. Boersma6, Dimitri Breems, MD, PhD7, Thomas Pabst, MD8, Lidwine Tick9, Peter JM Valk, PhD10, Bob Lowenberg, MD,PhD11, Gert J. Ossenkoppele, MD12, Marc Raaijmakers, MD13, Gerwin A. Huls, MD, PhD14, Jurjen Versluis Sr, MD, PhD15
AFFILIATIONS
1 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
2 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
3 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands, HOVON Foundation, Rotterdam, Netherlands
4 University Medical Center, University Groningen, Groningen, Netherlands
5 Meander Medical Center Amersfoort, Amersfoort, Netherlands
6 Amphia Hospital, Breda, Netherlands
7 ZAS Cadix Hospital, Antwerp, Belgium
8 Department of Medical Oncology, University Hospital, Inselspital, Bern, Switzerland, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
9 Maxima Medical Center, Veldhoven, Netherlands
10 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
11 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
12 Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, Netherlands
13 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
14 University Medical Center, University Groningen, Groningen, Netherlands
15 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, Netherlands
ABSTRACT
Introduction
Patients with acute myeloid leukemia (AML) are frequently unfit for intensive chemotherapy or venetoclax-based regimens due to advanced age and/or comorbidities. For these patients, treatment with hypomethylating agents (HMAs) can be considered. Myelodysplasia-related gene (MRG) mutations are associated with a poor prognosis in intensively treated AML patients, but their prognostic impact in the HMA-treated elderly population remains unclear. We evaluated the prognostic impact of MRG in elderly patients receiving HMAs monotherapy.
Methods
Newly diagnosed AML patients ineligible for intensive chemotherapy who were treated with HMAs in two HOVON-SAKK clinical trials (HO135 and HO155) were included. Patients in these trials were randomized to receive decitabine monotherapy (20 mg/m² for 5 or 10 days per cycle) or decitabine combined with ibrutinib (HO135) or midostaurin (HO155). Neither experimental drug affected overall survival (OS). We defined three mutually exclusive molecular subgroups: (1) TP53 mutated (TP53mut), defined by the presence of a TP53 mutation, (2) MRG mutated (MRGmut), defined by the presence of at least one of ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, or ZRSR2 gene mutations in the absence of TP53, and (3) genetically de novo AML, which had no TP53 or MRG mutations. Outcome parameters included early response, defined as achieving CR/CRi within 3 cycles of chemotherapy, and OS. OS was measured from randomization until death and estimated using the Kaplan–Meier method. A multivariable Cox proportional hazards regression model for OS was developed using a backward stepwise approach including variables with a p-value <0.2 in univariable analysis. Since nearly all TP53mut patients (34 out of 37 TP53mut with available cytogenetic data) harbored concurrent myelodysplasia-related cytogenetics, cytogenetics were omitted from the Cox model. The final multivariable model was adjusted for trial, arm (experimental or standard), age, baseline white blood cell (WBC) count, World Health Organization performance status, and molecular subgroup, as defined above.
Results
In total, 284 patients were treated in the two trials. The median age was 75 years (interquartile range [IQR], 72–78), and 38% of the patients were female. Sequencing data were available in 261/284 (92%) patients. Among these patients, 50 (19%) were TP53mut, 140 (54%) MRGmut, and 71 (27%) had genetically de novo AML. The most frequent MRG mutations were found in SRSF2 (26%) and ASXL1 (26%), followed by BCOR (10%), STAG2 (10%), U2AF1 (9%), SF3B1 (8%), EZH2 (8%), and ZRSR2 (2%). The median follow-up of the cohort was 24 months (IQR: 20-29).
Overall, CR within three cycles of decitabine was observed in 36% of patients, which was highest in the TP53mut subgroup (52%), 26% in the MRGmut, and 42% in genetically de novo AML (p=0.001). The median OS (mOS) for the entire cohort was 7.8 months (95%CI 6.1-11.3). Median OS was significantly shorter for the TP53mut and MRGmut subgroups compared with the genetically de novo subgroup (mOS 5.3 months, 95%CI 2.4- 12.3 and 6.6 months, 95%CI 4.7- 10.2 vs 12.2 months, 95%CI: 9.1–19.0; p=0.01 and p=0.02, respectively). In multivariable analysis, both TP53mut and MRGmut were significantly associated with shorter OS compared to genetically de novo AML (TP53: HR 1.98, 95%CI 1.30-3.03; p=0.001, MRG: HR 1.69, 95%CI 1.20-2.39; p=0.003). Focusing on the individual effect of the most common MRG, mutated ASXL1 was associated with significantly inferior OS in multivariable analysis in the TP53WT population (HR 1.54, 95%CI 1.10-2.17; p=0.01), whereas mutated SRSF2 was not associated with inferior OS (HR 1.13, 95%CI 0.81-1.58; p=0.46). Finally, among MRGmut patients, co-occurrence of FLT3-ITD, NRAS, or KRAS mutations (n=41), which is classified as intermediate risk according to ELN2024, was not associated with differential OS (HR 0.98, 95%CI 0.64–1.50, p=0.91) compared to MRGmut patients without those co-mutations (n=99).
Conclusion
Although AML with MRG without co-occurring FLT3-ITD and/or NRAS and/or KRAS is considered favorable risk in the non-intensive 2024 ELN classification system, MRG mutations identify a high-risk patient subpopulation with OS similar to TP53mut patients in patients treated with decitabine monotherapy. MRG confer resistance to decitabine treatment early on, with CR rates lower than those of TP53mut patients, suggesting that these patients might be considered for different induction strategies.
DISCLOSURES
Dimitrios Kotsos, MD, MSc: No relevant conflicts of interest to declare.